If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Patch testing is a diagnostic method used to identify substances that cause allergic contact dermatitis through a delayed hypersensitivity reaction. During the procedure, small amounts of potential allergens are applied to the skin, usually on the back, using adhesive patches containing standardized allergen preparations. The patches are typically left in place for 48 hours, after which the skin is examined for localized eczematous reactions. Additional readings are commonly performed 72–96 hours after application because allergic contact reactions may develop slowly. Unlike skin prick testing, which is used to diagnose immediate IgE-mediated allergies, patch testing evaluates delayed type IV hypersensitivity reactions mediated by T cells.
Albumin is a family of globular proteins, the most common of which are the serum albumins. All of the proteins of the albumin family are water-soluble, moderately soluble in concentrated salt solutions, and experience heat denaturation. Albumins are commonly found in blood plasma and differ from other blood proteins in that they are not glycosylated. Substances containing albumins are called albuminoids. A number of blood transport proteins are evolutionarily related in the albumin family, including serum albumin, alpha-fetoprotein, vitamin D-binding protein and afamin. This family is only found in vertebrates. Albumins in a less strict sense can mean other proteins that coagulate under certain conditions. See Other albumin types for lactalbumin, ovalbumin and plant "2S albumin". Albumins in general are transport proteins that bind to various ligands and carry them around. Human types include:
It is the heaviest doubly magic nuclide known. The four primordial isotopes of lead are all observationally stable, meaning that they are predicted to undergo radioactive decay but no decay has been observed yet. These four isotopes are predicted to undergo alpha decay and become isotopes of mercury which are themselves radioactive or observationally stable. There are trace quantities existing of the radioactive isotopes 209–214. The largest and most important is lead-210 as it has by far the longest half-life (22.2 years) and occurs in the abundant uranium decay series. Lead-211, -212, and -214 are present in the decay chains of uranium-235, thorium-232, and uranium-238, further, making these three lead isotopes also detectable in natural sources. The more minute traces of lead-209 arise from three rare decay branches: the beta-delayed-neutron decay of thallium-210 (in the uranium series), the last step of the neptunium series, traces of which are produced by neutron capture in uranium ores, and the very rare cluster decay of radium-223 (yielding also carbon-14). Lead-213 also occurs in a minor branch of the neptunium series. Lead-210 is particularly useful for helping to identify the ages of samples by measuring its ratio to lead-206 (both isotopes are present in a single decay chain). In total, 43 lead isotopes have been synthesized, from 178Pb to 220Pb.
Sources: en.wikipedia.org
University of Cincinnati Health (branded as UC Health) is the healthcare system of the University of Cincinnati, in Cincinnati, Ohio. It trains health care professionals and provides research and patient care. The system is affiliated with the university via the University of Cincinnati Academic Health Center (AHC). Most of the system's facilities are spread among two major campuses in the Cincinnati metropolitan area: the Clifton campus, home to the flagship University of Cincinnati Medical Center, and the West Chester campus, home to West Chester Hospital. There are also locations in Florence, Kentucky, and other Ohio communities.
=== Inside the continental crust === The continental crust, with tectonic fault zones could present a stable and well-protected environment for long-term prebiotic evolution. Inside these systems of cracks and cavities, water and carbon dioxide present the bulk solvents. Their phase state could vary between liquid, gaseous and supercritical, depending on pressure and temperature. When forming two separate phases, the system provides optimal conditions for phase transfer reactions. Concurrently, the contents of the tectonic fault zones are supplied with inorganic educts (e.g. carbon monoxide, hydrogen, ammonia, hydrogen cyanide, nitrogen, and phosphate) and simple organic molecules (e.g. amino acids, long-chain amines, fatty acids, long-chain aldehydes). Part of the tectonic fault zones is at a depth of around 1000 m. For carbon dioxide, it provides temperature and pressure conditions near the phase transition point between the supercritical and the gaseous state. This allows lipophilic organic molecules that dissolve well in supercritical CO2 to accumulate, leading to local precipitation. Periodic pressure variations such as caused by geysers or tidal influences result in periodic phase transitions, keeping the local reaction environment in a constant non-equilibrium state. In presence of amphiphilic compounds (such as the long chain amines and fatty acids), subsequent generations of vesicles are formed that are selected for their stability.
Since introducing its Narcotics Safety and Awareness Act, Ontario has committed to focusing on drug addiction, particularly in the monitoring and identification of problem opioid prescriptions, as well as the education of patients, doctors, and pharmacists. This Act, introduced in 2010, commits to the establishment of a unified database to fulfil this intention. Both the public and medical community have received the legislation positively, though concerns about the ramifications of legal changes have been expressed. Because laws are largely provincially regulated, many speculate a national strategy is needed to prevent smuggling across provincial borders from jurisdictions with looser restrictions. In 2015, Purdue Pharma's abuse-resistant OxyNEO and six generic versions of OxyContin had been on the Canada-wide approved list for prescriptions since 2012. In June 2015, then-federal Minister of Health Rona Ambrose announced that within three years, all oxycodone products sold in Canada would need to be tamper-resistant. Some experts warned that the generic product manufacturers may not have the technology to achieve that goal, possibly giving Purdue Pharma a monopoly on this opiate. Several class-action suits across Canada have been launched against the Purdue group of companies and affiliates. Claimants argue the pharmaceutical manufacturers did not meet a standard of care and were negligent in doing so. These lawsuits reference earlier judgments in the United States, which held that Purdue was liable for wrongful marketing practices and misbranding.
== Medical uses == In the United States, daptomycin is indicated for use in adults for skin and skin structure infections caused by Gram-positive infections, S. aureus bacteremia, and right-sided S. aureus endocarditis. In 2017, the FDA extended daptomycin's indications to pediatric patients aged 1 to 17 years: labeling for complicated skin and skin structure infections in this population was approved on 29 March 2017, and labeling for S. aureus bacteremia in pediatric patients was approved on 1 September 2017. Daptomycin is not recommended for patients younger than one year of age, given the potential for adverse effects on the muscular, neuromuscular, and nervous systems observed in neonatal animal studies. It binds avidly to pulmonary surfactant, and so is generally ineffective in treating pneumonia.
Sources: en.wikipedia.org
== Further reading == Brady JE, Humiston GE & Heikkinen H (1980), "Chemistry of the Representative Elements: Part II, The Metalloids and Nonmetals", in General Chemistry: Principles and Structure, 2nd ed., SI version, John Wiley & Sons, New York, pp. 537–91, ISBN 0-471-06315-0 Chedd G (1969), Half-way Elements: The Technology of Metalloids, Doubleday, New York Choppin GR & Johnsen RH (1972), "Group IV and the Metalloids", in Introductory Chemistry, Addison-Wesley, Reading, Massachusetts, pp. 341–57 Dunstan S (1968), "The Metalloids", in Principles of Chemistry, D. Van Nostrand Company, London, pp. 407–39 Goldsmith RH (1982), "Metalloids", Journal of Chemical Education, vol. 59, no. 6, pp. 526527, doi:10.1021/ed059p526 Hawkes SJ (2001), "Semimetallicity", Journal of Chemical Education, vol. 78, no. 12, pp. 1686–87, doi:10.1021/ed078p1686 Metcalfe HC, Williams JE & Castka JF (1974), "Aluminum and the Metalloids", in Modern Chemistry, Holt, Rinehart and Winston, New York, pp. 538–57, ISBN 0-03-089450-6 Miller JS (2019), "Viewpoint: Metalloids – An Electronic Band Structure Perspective", Chemistry – A European Perspective, preprint version, doi:10.1002/chem.201903167 Moeller T, Bailar JC, Kleinberg J, Guss CO, Castellion ME & Metz C (1989), "Carbon and the Semiconducting Elements", in Chemistry, with Inorganic Qualitative Analysis, 3rd ed., Harcourt Brace Jovanovich, San Diego, pp. 742–75, ISBN 0-15-506492-4 Parveen N et al.
Mark McVeigh (born 26 January 1981) is a former professional Australian rules footballer who played for and is currently the senior coach of the Essendon Football Club in the Australian Football League (AFL). He served as the caretaker senior coach of the Greater Western Sydney Giants following the resignation of Leon Cameron in 2022. He has been the senior coach of the Essendon Football Club since August 2026.
Structure-based drug design attempts to use the structure of proteins as a basis for designing new ligands by applying the principles of molecular recognition. Selective high affinity binding to the target is generally desirable since it leads to more efficacious drugs with fewer side effects. Thus, one of the most important principles for designing or obtaining potential new ligands is to predict the binding affinity of a certain ligand to its target (and known antitargets) and use the predicted affinity as a criterion for selection. One early general-purposed empirical scoring function to describe the binding energy of ligands to receptors was developed by Böhm. This empirical scoring function took the form:
== Analysis == The concentrations of individual compounds can be derived largely using the count rates of the precursor and product ions, and the reaction rate coefficients, k. Exothermic proton transfer reactions with H3O+ are assumed to proceed at the collisional rate (see Collision theory), the coefficient for which, kc, is calculable using the method described by Su and Chesnavich, providing the polarizability and dipole moment are known for the reactant molecule. NO+ and O2+ reactions proceed at kc less frequently, and thus the reaction rates of the reactant molecule with these precursor ions must often be derived experimentally by comparing the decline in the count rates of each of the NO+ and O2+ precursor ions to that of H3O+ as the sample flow of reactant molecules is increased. The product ions and rate coefficients have been derived in this way for well over 200 volatile compounds, which can be found in the scientific literature. The instrument can be programmed either to scan across a range of masses to produce a mass spectrum (Full Scan, FS, mode), or to rapidly switch between only the m/z values of interest (Multiple Ion Monitoring, MIM, mode). Due to the different chemical properties of the aforementioned precursor ions (H3O+, NO+, and O2+), different FS mode spectra can be produced for a vapor sample, and these can give different information relating to the composition of the sample. Using this information, it is often possible to identify the trace compound(s) that are present.
=== Decommunization === Stephen Holmes of the University of Chicago argued in 1996 that decommunization, after a brief active period, quickly ended in near-universal failure. After the introduction of lustration, demand for scapegoats has become relatively low, and former communists have been elected for high governmental and other administrative positions. Holmes notes that the only real exception was former East Germany, where thousands of former Stasi informers have been fired from public positions. Holmes suggests the following reasons for the failure of decommunization:
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.